Why Abzena?
Our focused approach.
ADCs are made up of three components: an antibody specific to the target associated antigen, a payload designed to kill target cancer cells, and a chemical linker to attach the payload to the antibody.
We have leading integrated development and manufacturing capabilities and expertise across all the ADC manufacturing components. Through our integrated capabilities for ADC products we can accelerate your timelines, de-risk and reduce program complexity, and effectively manage resources.
We support the robust scaling of ADC clinical through to commercial manufacturing. We are dedicated to quality excellence, delivering small molecule intermediates including high potency chemistry, payloads, linkers, payload-linker chemical intermediates, and bioconjugation.
Our ADC & bioconjugates commercial manufacturing and process development facilities utilize the same technologies to ensure effective scale up of your process, de-risking your overall commercial ADC program. We also ensure that any ADC technology transfer is successful and meets all product quality requirements.
Our scientific team have multiple decades of experience in the field of ADC production. We have robust and refined processes that have proven to accelerate customers programs and move ADCs forwards into clinical and commercial manufacturing.
We understand that ADC manufacturing is a complex multistep process which can be divided into three stages:
The conjugated antibodies then undergo extensive purification to remove therapeutic impurities. These are finished as ADC products upon the completion of fill-finishing.
Linker technologies are a critical component in the development and manufacturing of ADCs. Many linkers, particularly those used in first-generation ADC bioconjugation have limitations that can impact the safety and efficacy of the ADC.
ThioBridge™ has been developed by Abzena to overcome the limitations associated with traditional linker technologies. ThioBridge™ leverages our deep understanding and expertise in conjugation chemistry.
ThioBridge™ is important for the advancement of ADCs. ThioBridge™ provides several benefits for ADC development as it addresses issues commonly associated with traditional bioconjugation technologies by:
We enable you to bring life-changing medicines to patients in need faster. Let’s talk and move medicine forward.